Business
INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference
SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.\n\n \n \n \n \n \n \n\n \nThe Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website or at https://wsw.com/webcast/lytham4/invo/2054868. The webcast will also be archived and available for replay.\nManagement will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/spring2022invreg.\nAbout INVO Bioscience\nWe are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (\"ART\") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as \"IVC\", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (\"IVF\") and is a significantly more effective treatment than intrauterine insemination (\"IUI\"). Our commercialization strategy is focused on the opening of dedicated \"INVO Centers\" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.\nSafe Harbor Statement\nThis ...